It was shown that the activation of Sigma1R and BiP chaperones, which promotes increase in the protein folding capacity and adaptive UPR can be considered as an approach to pharmacotherapy of neurodegenerative diseases associated with accumulation of aberrant proteins (Figure 5). This evidence concerns the gene SIGMAR1 and neurodegenerative disease.